Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Corbus Pharmaceuticals Holdings was 41.60% per year. The lowest was -181.90% per year. And the median was -11.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Corbus Pharmaceuticals Holdings 3-Year EBITDA Growth Rate Related Terms
LTS:0SZI vs ANTX, ABOS, IMUX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.40% mean?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a 3-Year EBITDA Growth Rate of 10.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #621 out of 1124 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Corbus Pharmaceuticals Holdings' 3-Year EBITDA Growth Rate too high?
Corbus Pharmaceuticals Holdings' current 3-Year EBITDA Growth Rate is 10.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Corbus Pharmaceuticals Holdings' value of 10.40% is 29% below this industry median. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #621 out of 1124 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' 3-Year EBITDA Growth Rate compare to ANTX and ABOS?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #621 out of 1124 companies for 3-Year EBITDA Growth Rate. This places Corbus Pharmaceuticals Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Corbus Pharmaceuticals Holdings' value of 10.40% is 29% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corbus Pharmaceuticals Holdings's current 3-Year EBITDA Growth Rate of 10.40% is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current 3-Year EBITDA Growth Rate is 10.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.01, compared to a current price of $7.17 — trading 609.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 10.40% and 29% below the Biotechnology industry median of 14.65. Corbus Pharmaceuticals Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current 3-Year EBITDA Growth Rate is 10.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued.
The current stock price of $7.17 is trading 609.9% above its estimated GF Value™ of $1.01.
GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.
Key valuation signals for LTS:0SZI:
3-Year EBITDA Growth Rate: 10.40%
GF Value™: $1.01 vs. price of $7.17 (609.9% above fair value)
Industry Position: 29% below the Biotechnology median (#621 of 1124)
No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
39GF Score
Get the complete analysis for LTS:0SZI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0SZI has been successfully added to your 
